Cargando…
Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total chole...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650114/ https://www.ncbi.nlm.nih.gov/pubmed/26577580 http://dx.doi.org/10.1186/s12885-015-1928-z |
_version_ | 1782401449671524352 |
---|---|
author | Wulaningsih, Wahyu Vahdaninia, Mariam Rowley, Mark Holmberg, Lars Garmo, Hans Malmstrom, Håkan Lambe, Mats Hammar, Niklas Walldius, Göran Jungner, Ingmar Coolen, Anthonius C. Van Hemelrijck, Mieke |
author_facet | Wulaningsih, Wahyu Vahdaninia, Mariam Rowley, Mark Holmberg, Lars Garmo, Hans Malmstrom, Håkan Lambe, Mats Hammar, Niklas Walldius, Göran Jungner, Ingmar Coolen, Anthonius C. Van Hemelrijck, Mieke |
author_sort | Wulaningsih, Wahyu |
collection | PubMed |
description | BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total cholesterol (TC) measured prospectively 3 months to 3 years before diagnosis in 1798 Swedish women diagnosed with any type of BC between 1985 and 1999. In addition to using Cox regression, we employed latent class proportional hazards models to capture any heterogeneity of associations between these markers and BC death. The latter method was extended to include the primary outcome (BC death) and competing outcomes (CV death and death from other causes), allowing latent class-specific hazard estimation for cause-specific deaths. RESULTS: A lack of association between prediagnostic glucose, TG or TC with BC death was observed with Cox regression. With latent class proportional hazards model, two latent classes (Class I and II) were suggested. Class I, comprising the majority (81.5 %) of BC patients, had an increased risk of BC death following higher TG levels (HR: 1.87, 95 % CI: 1.01–3.45 for every log TG increase). Lower overall survival was observed in Class II, but no association for BC death was found. On the other hand, TC positively corresponded to CV death in Class II, and similarly, glucose to death from other causes. CONCLUSION: Addressing cohort heterogeneity in relation to BC survival is important in understanding the relationship between metabolic markers and cause-specific death in presence of competing outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1928-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4650114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46501142015-11-19 Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis Wulaningsih, Wahyu Vahdaninia, Mariam Rowley, Mark Holmberg, Lars Garmo, Hans Malmstrom, Håkan Lambe, Mats Hammar, Niklas Walldius, Göran Jungner, Ingmar Coolen, Anthonius C. Van Hemelrijck, Mieke BMC Cancer Research Article BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total cholesterol (TC) measured prospectively 3 months to 3 years before diagnosis in 1798 Swedish women diagnosed with any type of BC between 1985 and 1999. In addition to using Cox regression, we employed latent class proportional hazards models to capture any heterogeneity of associations between these markers and BC death. The latter method was extended to include the primary outcome (BC death) and competing outcomes (CV death and death from other causes), allowing latent class-specific hazard estimation for cause-specific deaths. RESULTS: A lack of association between prediagnostic glucose, TG or TC with BC death was observed with Cox regression. With latent class proportional hazards model, two latent classes (Class I and II) were suggested. Class I, comprising the majority (81.5 %) of BC patients, had an increased risk of BC death following higher TG levels (HR: 1.87, 95 % CI: 1.01–3.45 for every log TG increase). Lower overall survival was observed in Class II, but no association for BC death was found. On the other hand, TC positively corresponded to CV death in Class II, and similarly, glucose to death from other causes. CONCLUSION: Addressing cohort heterogeneity in relation to BC survival is important in understanding the relationship between metabolic markers and cause-specific death in presence of competing outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1928-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-17 /pmc/articles/PMC4650114/ /pubmed/26577580 http://dx.doi.org/10.1186/s12885-015-1928-z Text en © Wulaningsih et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wulaningsih, Wahyu Vahdaninia, Mariam Rowley, Mark Holmberg, Lars Garmo, Hans Malmstrom, Håkan Lambe, Mats Hammar, Niklas Walldius, Göran Jungner, Ingmar Coolen, Anthonius C. Van Hemelrijck, Mieke Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title | Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title_full | Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title_fullStr | Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title_full_unstemmed | Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title_short | Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
title_sort | prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650114/ https://www.ncbi.nlm.nih.gov/pubmed/26577580 http://dx.doi.org/10.1186/s12885-015-1928-z |
work_keys_str_mv | AT wulaningsihwahyu prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT vahdaniniamariam prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT rowleymark prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT holmberglars prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT garmohans prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT malmstromhakan prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT lambemats prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT hammarniklas prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT walldiusgoran prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT jungneringmar prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT coolenanthoniusc prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis AT vanhemelrijckmieke prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis |